Rapid review of multisystem inflammatory syndrome in paediatrics: What we know one year later
- PMID: 34880708
- PMCID: PMC8601103
- DOI: 10.14745/ccdr.v47i11a04
Rapid review of multisystem inflammatory syndrome in paediatrics: What we know one year later
Abstract
Background: : Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19) is an emerging condition that was first identified in paediatrics at the onset of the COVID-19 pandemic. The condition is also known as pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (PIMS-TS or PIMS), and multiple definitions have been established for this condition that share overlapping features with Kawasaki Disease and toxic shock syndrome.
Methods: : A review was conducted to identify literature describing the epidemiology of MIS-C, published up until March 9, 2021. A database established at the Public Health Agency of Canada with COVID-19 literature was searched for articles referencing MIS-C, PIMS or Kawasaki Disease in relation to COVID-19.
Results: : A total of 195 out of 988 articles were included in the review. The median age of MIS-C patients was between seven and 10 years of age, although children of all ages (and adults) can be affected. Multisystem inflammatory syndrome in children disproportionately affected males (58% patients), and Black and Hispanic children seem to be at an elevated risk for developing MIS-C. Roughly 62% of MIS-C patients required admission to an intensive care unit, with one in five patients requiring mechanical ventilation. Between 0% and 2% of MIS-C patients died, depending on the population and available interventions.
Conclusion: : Multisystem inflammatory syndrome in children can affect children of all ages. A significant proportion of patients required intensive care unit and mechanical ventilation and 0%-2% of cases resulted in fatalities. More evidence is needed on the role of race, ethnicity and comorbidities in the development of MIS-C.
Keywords: COVID-19; Keywords: multisystem inflammatory syndrome in children; MIS-C; PIMS; PIMS-TS; pediatric multisystem inflammatory syndrome.
Conflict of interest statement
Competing interests: None.
Figures
References
-
- European Centre for Disease Prevention and Control. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children ECDC; 2020 (accessed 2020-11-27). https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-risk-a...
-
- Centers for Disease Control and Prevention. Reporting Multisystem Inflammatory Syndrome in Children (MIS-C). Atlanta, GA: CDC; 2020 (accessed 2021-04-26). https://www.cdc.gov/mis-c/pdfs/hcp/MIS-Children-Handout-FINAL.pdf
-
- World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. Geneva, Switzerland: WHO; 2020 (accessed 2020-11-27). https://www.who.int/news-room/commentaries/detail/multisystem-inflammato...
-
- Centers for Disease Control and Prevention. Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C). Atlanta, GA; CDC: 2020 (accessed 2020-11-27). https://www.cdc.gov/mis-c/hcp/
-
- Royal College of Paediactrics and Child Health. Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS) - guidance for clinicians. London, UK: RCPCH; 2020 (accessed 2020-11-27). https://www.rcpch.ac.uk/resources/paediatric-multisystem-inflammatory-sy...
